-
-
-
-
-
-
-
Nuvalent Inc (NUVL) Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
-
-
-
-
-
-
-
AstraZeneca (AZN) reports Phase III trial of sipavibart long-acting antibody met primary endpoints
-
-
-
-
-
-
-
CASI Pharma (CASI) Receives FDA Clearance On The iNDA For CID-103
-
-
-
-
-
-
-
Curis (CRIS) Announces Additional Data from TakeAim Leukemia Study
-
-
-
-
-
-
-
Calliditas Therapeutics' (CALT) Partner Everest Medicines Starts Commercial Launch of Nefecon in China
-
-
-
-
-
-
-
Outlook Therapeutics (OTLK) Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
-
-
-
-
-
-
-
Merck (MRK) Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab
-
67,084 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.